BRPI0509299A - composto ou um sal, hidrato, ou solvato farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para a profilaxia ou o tratamento de doença, para reduzir ingestão de alimento de um indivìduo, para induzir saciedade em um indivìduo, para controlar ou reduzir ganho de peso em um indivìduo, para modular um receptor de mch em um indivìduo e para produzir uma composição farmacêutica - Google Patents
composto ou um sal, hidrato, ou solvato farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para a profilaxia ou o tratamento de doença, para reduzir ingestão de alimento de um indivìduo, para induzir saciedade em um indivìduo, para controlar ou reduzir ganho de peso em um indivìduo, para modular um receptor de mch em um indivìduo e para produzir uma composição farmacêuticaInfo
- Publication number
- BRPI0509299A BRPI0509299A BRPI0509299-0A BRPI0509299A BRPI0509299A BR PI0509299 A BRPI0509299 A BR PI0509299A BR PI0509299 A BRPI0509299 A BR PI0509299A BR PI0509299 A BRPI0509299 A BR PI0509299A
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- pharmaceutical composition
- reducing
- treatment
- disease
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000037406 food intake Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 102000029828 Melanin-concentrating hormone receptor Human genes 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 235000012631 food intake Nutrition 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 230000036186 satiety Effects 0.000 title 1
- 235000019627 satiety Nutrition 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 2
- 235000014632 disordered eating Nutrition 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000027559 Appetite disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010012218 Delirium Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000010235 Food Addiction Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000036528 appetite Effects 0.000 abstract 1
- 235000019789 appetite Nutrition 0.000 abstract 1
- 208000028683 bipolar I disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 102000006953 melanin-concentrating hormone receptor activity proteins Human genes 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
"COMPOSTO OU UM SAL HIDRATO, OU SOLVATO FARMACEUTICAMENTE ACEITáVEL DO MESMO, COMPOSIçãO FARMACêUTICA, E, MéTODOS PARA A PROFILAXIA OU O TRATAMENTO DE DOENçA, PARA REDUZIR INGESTãO DE ALIMENTO DE UM INDIVìDUO, PARA INDUZIR SACIEDADE EM UM INDIVìDUO, PARA CONTROLAR OU REDUZIR GANHO DE PESO EM UM INDIVìDUO, PARA MODULAR UM RECEPTOR DE MCH EM UM INDIVìDUO E PARA PRODUZIR UMA COMPOSIçãO FARMACêUTICA" A presente invenção compreende compostos de pirimidina substituída inéditos de Fórmula (I): que atuam como antagonistas de receptor de MCH. Estes compostos são úteis em composições farmacêuticas cujo uso inclui profilaxia ou o tratamento do melhoramento da função da memória, sono e vigília, ansiedade, depressão, distúrbios do humor, ataque apoplético, obesidade, diabetes, distúrbios do apetite e da alimentação, doença cardiovascular, hipertensão, dislipidemia, infarto miocárdico, distúrbios de alimentação compulsiva incluindo bulimia, anorexia, distúrbios mentais incluindo depressão maníaca, esquizofrenia, delírio, demência, estresse, distúrbios cognitivos, distúrbio do déficit de atenção, distúrbios do abuso de substância e discinesias incluindo doença de Parkinson, epilepsia, e adicção.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55740604P | 2004-03-30 | 2004-03-30 | |
PCT/JP2005/006582 WO2005095357A2 (en) | 2004-03-30 | 2005-03-29 | Pyrimidine derivatives and methods of treatment related to the use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0509299A true BRPI0509299A (pt) | 2007-09-18 |
Family
ID=35064444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0509299-0A BRPI0509299A (pt) | 2004-03-30 | 2005-03-29 | composto ou um sal, hidrato, ou solvato farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para a profilaxia ou o tratamento de doença, para reduzir ingestão de alimento de um indivìduo, para induzir saciedade em um indivìduo, para controlar ou reduzir ganho de peso em um indivìduo, para modular um receptor de mch em um indivìduo e para produzir uma composição farmacêutica |
Country Status (13)
Country | Link |
---|---|
US (1) | US20090036448A1 (pt) |
EP (1) | EP1730122A2 (pt) |
JP (1) | JP2007530445A (pt) |
KR (1) | KR20070013279A (pt) |
CN (2) | CN101693695A (pt) |
AU (1) | AU2005227997A1 (pt) |
BR (1) | BRPI0509299A (pt) |
CA (1) | CA2558915A1 (pt) |
NO (1) | NO20064950L (pt) |
NZ (1) | NZ549673A (pt) |
RU (1) | RU2373197C2 (pt) |
WO (1) | WO2005095357A2 (pt) |
ZA (1) | ZA200607639B (pt) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0512844D0 (en) * | 2005-06-23 | 2005-08-03 | Novartis Ag | Organic compounds |
US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
KR20110007258A (ko) | 2006-03-22 | 2011-01-21 | 에프. 호프만-라 로슈 아게 | 11-베타-hsd-1로서의 피라졸 |
JP2009531443A (ja) * | 2006-03-29 | 2009-09-03 | フォールドアールエックス ファーマシューティカルズ インコーポレーティッド | α−シヌクレイン毒性の抑制 |
CA2673586A1 (en) * | 2006-12-26 | 2008-07-24 | Amgen Inc. | N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases |
WO2008093737A1 (ja) | 2007-01-31 | 2008-08-07 | Dainippon Sumitomo Pharma Co., Ltd. | アミド誘導体 |
ES2757928T3 (es) * | 2007-08-02 | 2020-04-30 | Millennium Pharm Inc | Proceso para la síntesis de inhibidores de enzimas activadoras E1 |
US8273900B2 (en) * | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
ES2424393T3 (es) * | 2008-10-02 | 2013-10-01 | Taisho Pharmaceutical Co., Ltd. | Derivado de 7-piperidinalquil-3,4-dihidroquinolona |
US9187482B2 (en) | 2009-05-14 | 2015-11-17 | Millennium Pharmaceuticals, Inc. | Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
UA110097C2 (uk) * | 2009-09-02 | 2015-11-25 | Терапевтичний агент для лікування розладів настрою | |
KR101414012B1 (ko) | 2009-11-13 | 2014-07-01 | 주식회사 녹십자 | 아릴피페라진-함유 퓨린 유도체 및 그의 용도 |
CN102070618B (zh) * | 2009-11-23 | 2013-08-21 | 和记黄埔医药(上海)有限公司 | 一种化合物及其晶体 |
JP2013533287A (ja) * | 2010-07-27 | 2013-08-22 | テバ ファーマシューティカル インダストリーズ リミティド | 嗅覚機能不全の処置のためのラサギリンの使用 |
JP2015511940A (ja) | 2012-02-03 | 2015-04-23 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | 殺菌性ピリミジン化合物 |
WO2013113773A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113716A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113719A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds ii |
WO2013113778A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
EP2809659A1 (en) | 2012-02-03 | 2014-12-10 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113788A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113782A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113776A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113720A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113781A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds i |
EP2812324B1 (en) | 2012-02-08 | 2021-09-01 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
US9462809B2 (en) | 2012-03-13 | 2016-10-11 | Basf Se | Fungicidal pyrimidine compounds |
WO2013135672A1 (en) | 2012-03-13 | 2013-09-19 | Basf Se | Fungicidal pyrimidine compounds |
BR112015029970A2 (pt) * | 2013-06-06 | 2017-07-25 | Chiesi Farm Spa | inibidores de cinase |
WO2015036059A1 (en) | 2013-09-16 | 2015-03-19 | Basf Se | Fungicidal pyrimidine compounds |
CN105722833A (zh) | 2013-09-16 | 2016-06-29 | 巴斯夫欧洲公司 | 杀真菌的嘧啶化合物 |
US10308648B2 (en) | 2014-10-16 | 2019-06-04 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
CN104649981A (zh) * | 2015-02-11 | 2015-05-27 | 佛山市赛维斯医药科技有限公司 | 一种含嘧啶结构的对称环己烷羧酸苄基酰胺类双靶点抑制剂、制备方法及用途 |
CN104628656A (zh) * | 2015-02-11 | 2015-05-20 | 佛山市赛维斯医药科技有限公司 | 一类含嘧啶结构的对称环己烷羧酸酰胺类双靶点抑制剂及用途 |
CN104649980A (zh) * | 2015-02-11 | 2015-05-27 | 佛山市赛维斯医药科技有限公司 | 含嘧啶结构的对称环己烷羧酸酰胺类sglt2/sglt1双靶点抑制剂、制备方法及用途 |
CN104592131A (zh) * | 2015-02-11 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | 含嘧啶结构的对称环己烷羧酸苄基酰胺类化合物及用途 |
PL3331877T3 (pl) | 2015-08-04 | 2022-01-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Pochodna pirazolopirymidyny i jej zastosowania |
CN106632082B (zh) * | 2015-11-04 | 2020-10-09 | 中国科学院上海药物研究所 | 一类对gpr84具有激动作用的化合物及其制备方法和用途 |
AU2017275657B2 (en) | 2016-06-02 | 2021-08-19 | Novartis Ag | Potassium channel modulators |
US9975886B1 (en) | 2017-01-23 | 2018-05-22 | Cadent Therapeutics, Inc. | Potassium channel modulators |
CN114340670A (zh) | 2019-07-11 | 2022-04-12 | 普拉克西斯精密药物股份有限公司 | T-型钙通道调节剂的制剂及其使用方法 |
US10702525B1 (en) * | 2019-09-04 | 2020-07-07 | United Arab Emirates University | Pyrimidine derivatives as anti-diabetic agents |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4417163A1 (de) * | 1994-05-17 | 1995-11-23 | Hoechst Schering Agrevo Gmbh | Heterocyclylamino- und Heterocyclyloxy-cycloalkyl-Derivate, ihre Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide |
WO1996006086A1 (fr) * | 1994-08-23 | 1996-02-29 | Ube Industries, Ltd. | Derive de 4-cyclohexylaminopyrimidine, procede de production et produit utilise dans la lutte contre les parasites agrohorticoles |
WO1997020823A2 (en) * | 1995-12-01 | 1997-06-12 | Novartis Ag | 2-amino quinazoline derivatives as npy receptor antagonists |
KR100415791B1 (ko) * | 1998-06-19 | 2004-01-24 | 화이자 프로덕츠 인코포레이티드 | 피롤로[2,3-디]피리미딘 화합물 |
US6432969B1 (en) * | 2000-06-13 | 2002-08-13 | Novartis Ag | N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6849622B2 (en) * | 2000-10-06 | 2005-02-01 | Tanabe Seiyaku Co., Ltd. | Aliphatic nitrogenous five-membered ring compounds |
CA2460594A1 (en) * | 2001-10-01 | 2003-04-10 | Taisho Pharmaceutical Co., Ltd. | Mch receptor antagonists |
US7473695B2 (en) * | 2001-10-22 | 2009-01-06 | Mitsubishi Tanabe Pharma Corporation | 4-imidazolin-2-one compounds |
WO2003045313A2 (en) * | 2001-11-27 | 2003-06-05 | Merck & Co. Inc. | 2-aminoquinoline compounds |
EP1451156A4 (en) * | 2001-11-27 | 2005-05-25 | Merck & Co Inc | 4-AMINOQUINOLINE COMPOUNDS |
WO2003070244A1 (en) * | 2002-02-22 | 2003-08-28 | Abbott Laboratories | Antagonist of melanin concentrating hormone and their uses |
US6818772B2 (en) * | 2002-02-22 | 2004-11-16 | Abbott Laboratories | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
SE0202134D0 (sv) * | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Therapeutic agents |
WO2004067516A1 (en) * | 2003-01-30 | 2004-08-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta |
EP1464335A3 (en) * | 2003-03-31 | 2007-05-09 | Taisho Pharmaceutical Co. Ltd. | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist |
JP2004315511A (ja) * | 2003-03-31 | 2004-11-11 | Taisho Pharmaceut Co Ltd | Mch受容体アンタゴニスト |
EP1611109A4 (en) * | 2003-03-31 | 2009-06-24 | Taisho Pharmaceutical Co Ltd | NOVEL QUINAZOLINE DERIVATIVES AND THEIR THERAPEUTIC USE |
-
2005
- 2005-03-29 WO PCT/JP2005/006582 patent/WO2005095357A2/en active Application Filing
- 2005-03-29 EP EP05721721A patent/EP1730122A2/en not_active Withdrawn
- 2005-03-29 CA CA002558915A patent/CA2558915A1/en not_active Abandoned
- 2005-03-29 BR BRPI0509299-0A patent/BRPI0509299A/pt not_active IP Right Cessation
- 2005-03-29 CN CN200910173887A patent/CN101693695A/zh active Pending
- 2005-03-29 JP JP2006534511A patent/JP2007530445A/ja not_active Abandoned
- 2005-03-29 NZ NZ549673A patent/NZ549673A/en unknown
- 2005-03-29 RU RU2006138022/04A patent/RU2373197C2/ru not_active IP Right Cessation
- 2005-03-29 ZA ZA200607639A patent/ZA200607639B/en unknown
- 2005-03-29 US US10/599,505 patent/US20090036448A1/en not_active Abandoned
- 2005-03-29 CN CNA200580017519XA patent/CN1976905A/zh active Pending
- 2005-03-29 AU AU2005227997A patent/AU2005227997A1/en not_active Abandoned
- 2005-03-29 KR KR1020067020312A patent/KR20070013279A/ko not_active Application Discontinuation
-
2006
- 2006-10-30 NO NO20064950A patent/NO20064950L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2005227997A1 (en) | 2005-10-13 |
RU2006138022A (ru) | 2008-05-10 |
KR20070013279A (ko) | 2007-01-30 |
EP1730122A2 (en) | 2006-12-13 |
JP2007530445A (ja) | 2007-11-01 |
RU2373197C2 (ru) | 2009-11-20 |
WO2005095357A2 (en) | 2005-10-13 |
WO2005095357A3 (en) | 2006-01-19 |
ZA200607639B (en) | 2008-05-28 |
CN101693695A (zh) | 2010-04-14 |
NZ549673A (en) | 2010-03-26 |
CN1976905A (zh) | 2007-06-06 |
NO20064950L (no) | 2006-12-29 |
US20090036448A1 (en) | 2009-02-05 |
CA2558915A1 (en) | 2005-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0509299A (pt) | composto ou um sal, hidrato, ou solvato farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para a profilaxia ou o tratamento de doença, para reduzir ingestão de alimento de um indivìduo, para induzir saciedade em um indivìduo, para controlar ou reduzir ganho de peso em um indivìduo, para modular um receptor de mch em um indivìduo e para produzir uma composição farmacêutica | |
BRPI0408910A (pt) | composto, composição farmacêutica e métodos para a profilaxia ou o tratamento de doenças ou condições e para a produção de uma composição farmacêutica | |
TW200626152A (en) | Pyridine derivatives and pharmaceutical compositions and uses thereof | |
BRPI0925343A2 (pt) | Composto, composição farmacêutica, e, droga profilática ou terapêutica | |
WO2006012577A3 (en) | Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake | |
MX2009011358A (es) | Derivados de pirimidinona y metodos para su uso. | |
EA200800430A1 (ru) | Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов | |
BRPI0811842A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos para aumentar a qualidade do sono em um paciente mamífero, para tratar a insônia em um paciente mamífero, e para tratar ou controlar a obesidade em um paciente mamífero | |
EA200601546A1 (ru) | 6-ЗАМЕЩЁННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-БЕНЗО[d]АЗЕПИНЫ В КАЧЕСТВЕ АГОНИСТОВ РЕЦЕПТОРОВ 5-HT | |
PE20081800A1 (es) | NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA | |
TW200630360A (en) | Polymorphs of {5-[3-(4,6-difluoro-1H-benzoimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine | |
ZA200706354B (en) | Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses | |
CL2008003339A1 (es) | Compuestos derivados de pirimidin-2(1h)-ona, inhibidores de la 11b-hidroxiesteroide deshidrogenasa 1; composicion farmaceutica, util para el tratamiento de enfermedades tales como obesidad, hipertension e hiperlipidemia. | |
NO20083369L (no) | Anvendelse av substituert 2-imidazol av imidazolinderivater | |
GB0504857D0 (en) | Novel compounds and their effects on feeding behaviour | |
TW200628452A (en) | Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents | |
WO2006064375A2 (en) | Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases | |
TW200719886A (en) | Dihydrobenzofuran derivatives and uses thereof | |
MX2009005358A (es) | Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2. | |
GEP20104880B (en) | Carboxamide derivatives as muscarinic receptor antagonists | |
TW200800959A (en) | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor | |
RS53286B (en) | POLYMORPHIC FORMS (2S) - (4E) -N-METHYL-5- [3- (5-ISOPROPOXYPRIDINE) IL] -4-PENTEN-2-AMINE P-HYDROXYBENZOATE IN THERAPY-DISORDER THERAPY | |
MX2010009536A (es) | Amidas de acido 5-oxo-2,3,4,5-tetrahidro-benzo[b]oxepin-4-carboxil ico y amidas de acido 2,3-dihidro-benzo[b]oxepin-4-carboxilico para el tratamiento y la prevension de la diabetes tipo 1 y 2. | |
WO2006044762A3 (en) | Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor | |
CR9622A (es) | Derivados de pirazolo[3,4-d]azepina como antagonistas de histamina h3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013. |